At the helm of this research is Professor David Drew from Stockholm University, whose team, in collaboration with researchers across Europe and Japan, has marveled at the intricate molecular choreography governing ATP translocation into the ER. By employing cutting-edge cryo-electron microscopy (cryo-EM), they elucidated high-resolution structures of SLC35B1, visualizing the transporter in multiple conformational states. These structural snapshots have unraveled the mechanistic underpinnings of how SLC35B1 effectively recognizes and facilitates the passage of ATP molecules from the cytosol into the ER interior, a compartment critical for cellular homeostasis.

The ER functions as a cellular nexus, orchestrating the synthesis, folding, and trafficking of proteins and lipids essential for cell survival. These energetically demanding processes rely heavily on ATP, whose precise delivery into the ER has remained an unresolved mystery due to the organelle’s isolation from direct ATP synthesis and cytosolic ATP pools. The confirmation of SLC35B1 as the ATP transporter fills this vital knowledge gap, fundamentally advancing our comprehension of intracellular energy logistics.

Intriguingly, the data show that SLC35B1 operates through a step-wise translocation mechanism, involving specific binding sites that selectively recognize ATP’s physiochemical properties. The cryo-EM structures detail key amino acid residues integral to ATP binding and conveyance, highlighting prospective molecular targets for drug design. By modulating these critical residues, future therapies could influence ATP transport efficiency, offering novel interventions for managing ER stress-related pathologies.

Diseases such as type 2 diabetes, various cancers, and neurodegenerative disorders like Alzheimer’s disease have all been linked to impaired ER function characterized by energy imbalance and protein misfolding. The ability to alter ATP supply within the ER through pharmacological agents targeting SLC35B1 is poised to revolutionize treatment paradigms. Enhanced ATP delivery could restore ER homeostasis in conditions marked by energy deficits, while downregulating transport might suppress aberrant activities in pathological states where ER stress fuels disease progression.

Particularly notable is the interdisciplinary approach behind this advance. Early attempts at identifying the ATP transporter candidate were confounded by conflicting reports and scant biochemical validation. To resolve this, the team leveraged a large-scale CRISPR/Cas9 knockout screening conducted collaboratively with the Giulio Superti-Furga Lab at Austria’s CeMM. This functional genomics approach ranked SLC35B1 among the top five crucial transporters for cellular viability, consolidating its role in ATP transport.

Further experimental validation came from the generation of a highly specific antibody against human SLC35B1 by Norimichi Nomura’s group at Kyoto Medical School. This antibody proved indispensable for stabilizing the transporter protein, effectively increasing its molecular size to a threshold amenable for cryo-EM imaging. Without this step, capturing detailed structural information of such a relatively small membrane protein would have remained elusive, demonstrating the ingenuity behind the methodological advancements.

Professor Drew emphasizes that the uncovered molecular blueprint extends beyond fundamental biology into translational medicine. By revealing SLC35B1’s conformational dynamics and ATP-binding motifs, the study provides a scaffold for the rational design of small molecules capable of fine-tuning transporter activity. Therapeutic modulation could either safeguard ER function by enhancing ATP import in disease states or inhibit it where pathological ER hyperactivity contributes to disease.

Currently, the research consortium is actively screening compound libraries for small molecules that can specifically interact with SLC35B1. These efforts aim to identify candidate molecules capable of modulating ATP transport, thereby paving the way for targeted therapies that rectify ER-related metabolic imbalances. Such drug candidates could usher in a new class of treatments addressing the root causes of ER-associated disorders.

The ramifications of this discovery also resonate with broader cellular physiology, as it sheds light on energy distribution mechanisms within organelles. Understanding how ATP is selectively delivered and consumed within intracellular compartments is a fundamental biological problem with implications across metabolism, signaling, and cell survival pathways. This study places SLC35B1 at the center of this intricate web, providing a tangible target for further exploration.

From a technical standpoint, the study showcases how modern structural biology techniques such as cryo-EM have transformed our ability to visualize membrane proteins in action. By capturing SLC35B1 in multiple functional states, the researchers not only confirm its role but also reveal the dynamic conformational landscape that underpins transporter function. This insight is essential for any future endeavors seeking to manipulate transporter behavior pharmacologically.

Ultimately, this seminal research on SLC35B1 catalyzes a paradigm shift in how we perceive organellar bioenergetics and its linkage to disease. As we deepen our grasp on molecular transport mechanisms, we open avenues to innovative therapeutic strategies that target intracellular energy pathways. The promise of controlling ATP flow within the ER is poised to impact a wide spectrum of diseases where cellular energy dysregulation is pathogenic.

In summary, the identification and detailed characterization of SLC35B1 as the human ER ATP transporter resolves a pivotal question in cell biology and medicine. This work exemplifies the power of multidisciplinary collaboration combining structural biology, biochemistry, genetics, and chemical biology to untangle complex cellular phenomena. With ongoing drug discovery efforts, the path from fundamental discovery to clinical application looks increasingly attainable, heralding a new frontier in combating ER-associated human diseases.

Subject of Research: Cells

Article Title: Step-wise ATP translocation into the ER by human SLC35B1

News Publication Date: 21-May-2025

Web References: https://www.nature.com/articles/s41586-025-09069-w

References: DOI: 10.1038/s41586-025-09069-w

Image Credits: Made by Surabhi Kokane using Biorender.com

Keywords: ATP transport, SLC35B1, endoplasmic reticulum, cryo-electron microscopy, membrane transporter, ER stress, protein folding, cellular bioenergetics, targeted therapy, molecular structure, CRISPR/Cas9 screening, drug discovery

Cells are constantly challenged by fluctuations in their environment, with temperature shifts representing among the most severe stressors. Thermal stress can disrupt protein folding and damage cellular components, necessitating robust quality control and adaptive mechanisms to maintain homeostasis. The study meticulously dissects the crosstalk between CMA and mitochondrial function, with particular emphasis on how this interaction preserves cellular energy balance during and after episodes of elevated temperature.

PGC1α, the peroxisome proliferator-activated receptor gamma coactivator 1-alpha, functions as a master regulator orchestrating mitochondrial biogenesis and energy metabolism. Its activity is normally tightly regulated at multiple levels including transcription, post-translational modifications, and protein turnover. The research reveals that under thermal stress, CMA selectively targets specific proteins to modulate the stability and activity of PGC1α, ensuring the cell’s metabolic machinery adapts swiftly to environmental challenges.

The authors utilized a combination of molecular biology, imaging, and metabolic flux analyses to demonstrate that CMA promotes the selective degradation of inhibitory factors that otherwise destabilize PGC1α. This selective autophagic process thus indirectly enhances PGC1α stability, allowing the activation of downstream transcriptional programs that boost mitochondrial function and energy production. Such an adaptive response equips the cell with increased resilience against thermal perturbation.

Intriguingly, the study also shows that suppression of CMA activity, either genetically or pharmacologically, leads to significant metabolic dysfunction when cells are exposed to heat stress. This finding underscores the essential nature of CMA in maintaining energy homeostasis under adverse conditions. Cells deficient in CMA displayed reduced mitochondrial content, decreased ATP production, and impaired recovery from metabolic stress, highlighting the pathway’s protective role.

Beyond fundamental cell biology, this research has profound implications for understanding how organisms manage metabolic challenges in fluctuating environments. Thermal stress is common not only in pathological contexts such as fever but also in occupational and environmental exposures. Unraveling the mechanism by which CMA regulates PGC1α stability enriches our grasp of cellular flexibility and survival mechanisms, potentially informing treatments for diseases linked with mitochondrial dysfunction, including neurodegenerative diseases and metabolic syndromes.

The intricate regulation of protein quality control pathways like CMA is a testament to the cell’s evolutionary ingenuity. Unlike bulk autophagy, CMA selectively recognizes specific protein substrates containing KFERQ-like motifs, directing them for lysosomal degradation. This selectivity allows precise control of key regulatory proteins such as PGC1α, ensuring timely and context-dependent metabolic adjustments. By focusing on CMA’s role in thermal stress, this study adds a new dimension to our understanding of autophagic regulation of metabolism.

Technically, the researchers employed state-of-the-art proteomics to identify CMA substrates and used live-cell imaging to monitor mitochondrial dynamics in real time. Results indicated that heat-induced activation of CMA is a finely-tuned process that balances protein clearance with metabolic demand. Notably, they observed heightened CMA activity correlating with increased mitochondrial biogenesis, a response that mitigates the deleterious effects of thermal damage on energy production.

The researchers also dissected the signaling cascades upstream of CMA activation during thermal stress, elucidating involvement of pathways that sense protein misfolding and oxidative stress. These signaling networks coordinate CMA induction, linking environmental cues to cellular metabolic adaptations. Furthermore, the study explored how modulation of CMA influences reactive oxygen species (ROS) levels, which are critical indicators of mitochondrial health and stress status.

Such insights provide a molecular framework explaining how CMA serves as a linchpin integrating proteostasis and metabolic regulation. The study’s data show that by stabilizing PGC1α, CMA indirectly supports the transcriptional activation of genes involved in oxidative phosphorylation, fatty acid oxidation, and antioxidant defense. Consequently, the cell enhances its capacity to generate ATP efficiently while minimizing oxidative damage, an essential balance for survival under thermal stress.

This investigation also touches upon the potential connection between CMA dysregulation and age-related decline in mitochondrial function. Given that CMA efficiency diminishes with age, impaired PGC1α stability might underlie some metabolic deficits observed in elderly tissues. The authors propose that therapeutic enhancement of CMA could rejuvenate metabolic flexibility and protect against diseases characterized by mitochondrial decay.

In exploring therapeutic potential, the authors speculate on pharmacological agents capable of modulating CMA activity. Such compounds could provide targeted intervention avenues to restore mitochondrial health, not only under stress conditions but also in chronic metabolic diseases. However, they caution that precise tuning of CMA is required, as unregulated autophagy might trigger undesired degradation of vital proteins.

The study’s comprehensive approach also included in vivo models demonstrating that organisms with enhanced CMA activity show superior thermal tolerance and metabolic adaptation. This reinforces the translational relevance of the findings and inspires future research in physiological and clinical contexts including fever response, heat stroke, and metabolic syndrome.

Collectively, this research presents a paradigm shift in our understanding of cellular adaptation to thermal stress, positioning chaperone-mediated autophagy as a critical guardian of energy metabolism through the stabilization of PGC1α. The findings illuminate intricate layers of metabolic regulation and underscore the potential of targeting CMA to mitigate metabolic and stress-related diseases.

As the scientific community delves deeper into the intersections of autophagy, proteostasis, and metabolism, studies such as this pave the way toward innovative therapeutic strategies. By revealing the nuanced role CMA plays in modulating cellular energy homeostasis, Zhuang and colleagues contribute a vital piece to the complex puzzle of how cells endure and thrive amid environmental adversities.

The implications of these findings extend beyond heat stress, inviting investigation into CMA’s role in other forms of cellular insults such as hypoxia, nutrient deprivation, and oxidative damage. Future research building on this foundation promises to unveil novel mechanisms of cellular resilience and inform diverse biomedical applications.

Ultimately, this study not only challenges existing dogma but also invigorates the field of metabolic research with fresh insights into the dynamic regulation of mitochondrial function. It serves as a sterling example of how the interplay between selective autophagy and metabolic control is essential to cellular survival and function in a fluctuating environment.

Subject of Research: Chaperone-mediated autophagy regulation of PGC1α stability and energy metabolism under thermal stress.

Article Title: Chaperone-mediated autophagy manipulates PGC1α stability and governs energy metabolism under thermal stress.

Article References:

Zhuang, Y., Zhang, X., Zhang, S. et al. Chaperone-mediated autophagy manipulates PGC1α stability and governs energy metabolism under thermal stress. Nat Commun 16, 4455 (2025). https://doi.org/10.1038/s41467-025-59618-0

Image Credits: AI Generated

The background of this research is rooted in understanding the multifaceted role PDIs play in maintaining cellular homeostasis. RA, characterized by chronic inflammation and joint destruction, poses significant challenges not only to the patient’s quality of life but also to healthcare systems worldwide. The convergence of cancer biology and autoimmune pathology suggests that repositioning existing therapies like EFC could revolutionize treatment paradigms for RA. By inhibiting PDIs, EFC may effectively alter the inflammatory microenvironment typical of RA.

The methods prescribed in this exploration involved a robust set of assays meticulously designed to elucidate EFC’s effects on fibroblast-like synoviocytes (FLSs), which are crucial in the pathogenesis of RA. Utilizing the Cell Counting Kit-8 (CCK-8), researchers quantified cell viability, revealing crucial insights into the cytotoxic effects of EFC on RA FLSs. Proliferation was assessed using the EdU incorporation assay, which provided a clear measure of cellular growth inhibition, crucial in understanding the therapeutic potential of EFC.

Furthermore, the migration and invasion capabilities of FLSs were examined through Transwell assays. These experiments aimed to characterize the influence of EFC on a critical aspect of RA pathology: the aggressive migration of synoviocytes into the joint space, where they exacerbate inflammation. Coupled with TUNEL assays which evaluated apoptotic cells, the data obtained painted a comprehensive picture of EFC’s multifaceted actions within the RA context.

To investigate angiogenesis, an in vitro tube formation assay was employed. This aspect is particularly relevant given that neovascularization is a prominent feature in inflamed RA joints, facilitating the persistence of chronic inflammation. This investigative phase was complemented by rigorous flow cytometry techniques, enabling precise apoptotic profiling, affirming EFC’s potential to shift the balance of cell survival and death in RA.

In vivo assessments further solidified EFC’s therapeutic promise. A collagen-induced arthritis model, widely regarded as a gold standard for RA research, was employed in DBA mice. This model allowed the researchers to draw critical connections between EFC treatment and alterations in inflammatory response, disease progression, and bone integrity. Radiographic analyses combined with histological evaluations provided compelling evidence of EFC’s protective effects against joint damage.

The results of this comprehensive study highlighted EFC’s profound anti-inflammatory effects, evidenced by decreased cell proliferation, diminished cytokine secretion, and enhanced apoptosis in RA FLSs. In vivo findings corroborated these observations, demonstrating that EFC not only alleviated joint inflammation but also exhibited protective properties against bone and cartilage deterioration. This pharmacological intervention introduced a striking shift in the disease’s trajectory, underscoring the importance of innovative approaches in RA management.

Among the pivotal findings was RNA sequencing data, which illuminated the intricate molecular pathways influenced by EFC treatment. Notably, the pathways associated with inflammation and apoptosis regulation were markedly modulated, shedding light on the mechanistic underpinnings of EFC’s therapeutic efficacy. This revelation not only reinforces the significance of PDIs in RA but also highlights the potential for developing targeted therapies aimed at these molecular pathways.

In conclusion, the investigation into EFC’s role as a PDI inhibitor illustrates a promising new direction in RA treatment research. The capacity of EFC to mitigate inflammatory responses and restore balance within the immune system positions it as a groundbreaking therapeutic candidate. The insights gained from this study not only augment our understanding of RA pathology but also necessitate further exploration into PDIs as viable targets for therapeutic intervention.

By bolstering the nexus between cancer therapy and autoimmune treatment, researchers advocate for a reevaluation of existing drugs. This opportunistic approach may facilitate optimized utilization of established medications, heralding a new era in RA management. Future clinical trials will be essential in translating these compelling preclinical findings into tangible benefits for RA patients globally.

The exploration of EFC extends beyond the immediate implications for RA; it sets a precedent for how innovative applications of existing therapies can reshape our understanding of various diseases. As the medical community grapples with the complexities of inflammatory disorders, the advances presented in this study serve as a beacon of hope in the quest for more effective treatments.

The insights derived from this research not only highlight the therapeutic potential of EFC but also the importance of interdisciplinary approaches in addressing chronic diseases. As new challenges arise in the management of RA and similar conditions, the lessons learned from this study could inform future research and therapeutic strategies.

Subject of Research: The Effectiveness of E64FC26 in Treating Rheumatoid Arthritis
Article Title: E64FC26, a Protein Disulfide Isomerase Inhibitor, Ameliorates Articular Cartilage Damage and Disease Severity in a Mouse Model of Rheumatoid Arthritis
News Publication Date: 25-Jan-2025
Web References: Exploratory Research and Hypothesis in Medicine
References: DOI 10.14218/ERHM.2024.00033
Image Credits: Jinxiang Han, Lin Wang, Haiyan Zhao, Ting Wang

Keywords: Rheumatoid arthritis, Drug therapy, Inflammation